Article Impact Level: HIGH Data Quality: STRONG Summary of Science Translational Medicine https://doi.org/10.1126/scitranslmed.adz1280 Dr. Naomi Vlegels et al.
Points
- This longitudinal study of over twelve hundred stroke patients demonstrated that brain derived tau concentrations measured at admission can accurately predict final infarct volumes and initial neurological damage levels.
- Researchers found that significant increases in biomarker levels within the first forty eight hours after a stroke are directly associated with the physical growth of the ischemic brain infarct.
- The marker successfully detected differences in treatment outcomes for patients undergoing mechanical thrombectomy as complete vessel reopening resulted in a much smaller rise in circulating brain derived tau protein.
- Data from a phase three clinical trial revealed that the neuroprotective drug nerinetide reduced the increase of this biomarker by forty nine percent compared to the administered placebo group.
- Testing showed that this specific blood marker outperforms standard magnetic resonance imaging in predicting functional recovery outcomes for patients at three months and up to three years after injury.
Summary
This study evaluated plasma brain-derived tau (BD-tau) as a longitudinal biomarker for monitoring acute ischemic brain injury, addressing the clinical limitation of point-in-time imaging. Utilizing data from over 1,200 patients across three cohorts—including a 502-patient discovery group and a phase 3 clinical trial—researchers assessed BD-tau via single-molecule detection assays. Unlike systemic markers, BD-tau selectively quantifies tau protein originating from the central nervous system, providing a high-fidelity representation of neuronal damage dynamics from hospital admission through day 7.
Higher BD-tau concentrations at admission significantly correlated with early injury extent on computed tomography and predicted final infarct volumes. Analysis showed that increases in concentrations between admission and day 2 were specifically associated with infarct growth, while levels peaked around day 7 in patients experiencing secondary neurological events or recurrent strokes. Furthermore, BD-tau outperformed traditional imaging metrics and other blood markers in predicting functional recovery at 90 days, 12 months, and 36 months, maintaining high predictive accuracy across various infarct size strata.
The marker also demonstrated utility in assessing treatment efficacy and vascular recanalization success. In patients undergoing mechanical thrombectomy, complete vessel reopening was associated with a markedly smaller rise in BD-tau compared to cases of incomplete recanalization. Additionally, in a biomarker substudy of 193 patients, the neuroprotectant nerinetide resulted in a 49% smaller increase in BD-tau levels versus a placebo. These findings suggest that BD-tau can serve as a “brain troponin” for real-time monitoring of injury progression and as a surrogate endpoint for clinical research
Link to the article: https://www.science.org/doi/10.1126/scitranslmed.adz1280
References
Vlegels, N., Knuth, N. L., Steiner, K. A., Zhang, L., Vix, A. L., Moumin, D., Mirzen, I., Khalifeh, N., Forster, C., Gesierich, B., Müller, F., Lohse, P., Filler, J., Fang, R., Klein, M., Dimitriadis, K., Franzmeier, N., Liebig, T., Endres, M., … Stockero, A. (2026). Brain-derived tau for monitoring brain injury in acute ischemic stroke. Science Translational Medicine, 18(832), eadz1280. https://doi.org/10.1126/scitranslmed.adz1280
